PROTHROMBIN COMPLEX INJ,LYPHL
Clinical Criteria Summary
Document 141: Prothrombin Complex Concentrate 4 Factor Kcentra Recommendations for Use
Exclusion Criteria
- Patient with disseminated intravascular coagulation (DIC)
- History of heparin-induced thrombocytopenia (HIT)
- History of anaphylactic or severe systemic reaction to 4F-PCC or any components (heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III, human albumin)
- Situation in which administration of intravenous vitamin K and withdrawal of warfarin therapy alone would adequately reverse anticoagulation within the required timeframe for an urgent invasive procedure or surgery
- Patients in whom complete correction of International Normalized Ratio (INR) is not clinically appropriate or necessary
Inclusion Criteria
- Receiving treatment with a vitamin K antagonist (e.g., warfarin) therapy with INR ≥ 2 AND standard measures for bleeding cessation/reversal are contraindicated or insufficient
- Co-administration with vitamin K is required
- PLUS ONE of the following indications:
- Acute life-threatening major bleeding (including intracranial hemorrhage)
- Need for urgent life-saving surgery or invasive procedure
Dosage and Administration
- Administered as a single dose IV infusion based on pre-treatment INR and actual body weight
- Dosing calculated based on the quantity of factor IX in the product (varies by vial potency)
- Pre-treatment dosing table:
- INR 2 to <4: 25 IU/kg (Maximum dose: 2500 IU)
- INR 4 to 6: 35 IU/kg (Maximum dose: 3500 IU)
- INR >6: 50 IU/kg (Maximum dose: 5000 IU)
- Dosing based on actual body weight up to 100 kg; do not exceed maximum doses for patients weighing >100 kg
- Do not mix with other products; administer through a separate infusion line
- Administer at a rate of 0.12 mL/kg/min, up to a maximum rate of 8.4 mL/min
- No blood should enter the syringe (risk of fibrin formation)
- Repeat dosing is not recommended as effectiveness and safety have not been established
Monitoring
- Use a current, pre-treatment INR taken close to the time of 4F-PCC dosing due to potential fluctuations in acute bleeding or urgent settings
- Evaluate laboratory coagulation parameters alongside clinical signs of hemostasis and thromboembolism post-administration
Clinical Considerations & Risk Management
- Thromboembolic Risk: Carries a Boxed Warning for arterial and venous thromboembolic complications. High-risk populations excluded from trials include patients with recent history (within last 3 months) of thrombotic event, myocardial infarction, cerebrovascular accident, transient ischemic attack, unstable angina pectoris, severe peripheral vascular disease, or DIC; known antiphospholipid syndrome; known inhibitors to coagulation factors II, VII, IX, or X; and known hereditary protein C or protein S deficiency.
- Non-warfarin Oral Anticoagulants: Insufficient clinical evidence for off-label use; not FDA approved. Consider only in severe, life-threatening situations where all other measures have failed or are not indicated. Weak preference noted for activated PCC (FEIBA) for dabigatran reversal and 4F-PCC for rivaroxaban/apixaban reversal.
- Fluid Status: Associated with a numerically lower rate of fluid overload or cardiac events compared to plasma. Mean infused volume <100 mL. May be preferred if patient cannot tolerate additional plasma volume.
- Timing of Reversal: Superior INR correction at 30 minutes to 12 hours post-infusion compared to plasma; difference not evident at 24 hours. Preferable for rapid reversal within 24 hours (e.g., intracranial hemorrhage, life-threatening bleeding, urgent surgery). No significant difference in effective hemostasis at 24 hours, mortality, or length of hospital stay.
- History of HIT: Contains heparin; history of HIT is a contraindication per FDA labeling. May be considered if patient has negative antibody testing for life-threatening bleeding requiring cardiac surgery (per ACCP guidelines), though evidence is limited.
- Infectious Disease Transmission: Blood-derived product carries infection risk despite two virus reduction steps.
- Pregnancy and Childbearing Potential: Reserve for life-threatening instances; weigh risks and benefits to mother and fetus. Category C; not studied in pregnancy.
Document 225: Direct Oral Anticoagulants DOAC Reversal Recommendations for Use Jan 2026
Criteria for Idarucizumab (Praxbind)
- Applies to: Dabigatran
- Indication/Use: Reversal of dabigatran in the setting of bleeding or emergent surgery/urgent procedures.
- Inclusion Criteria (ALL must be met):
- Patient has been taking dabigatran, and provider is reasonably certain that therapeutic anticoagulant levels are present (e.g., patient history and timing of last dose, laboratory testing if available).
- Patient has life-threatening or critical site bleeding (e.g., ICH) OR is in need of a truly emergent procedure that cannot be delayed for at least 8 hours and where normal hemostasis is required.
- If reversal is desired in the setting of bleeding, standard measures for bleeding management (e.g., discontinuing anticoagulant, compression, surgical repair, fluid and/or blood replacement, hemodynamic support) are insufficient.
- Patient’s risk of thromboembolism is deemed less than the consequences of continued bleeding or delay of the procedure or surgery.
- Issues for Consideration:
- Specific for dabigatran only; will not reverse effects of other anticoagulants including Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban) or other direct thrombin inhibitors (e.g., argatroban, bivalirudin).
- Not known to exhibit procoagulant effects.
- Reversing anticoagulation exposes patients to thrombotic risk of underlying disease; 4.8% experienced a thromboembolic event within 30-day follow-up in REVERSE-AD. Consider restarting anticoagulant therapy as soon as medically appropriate (dabigatran can be started 24 hours after idarucizumab administration).
- Hypersensitivity reactions have been reported.
- Patients with hereditary fructose intolerance: Serious adverse reactions/death reported with parenteral sorbitol; recommended dose contains 4 g of sorbitol excipient. Consider combined metabolic load from all sources.
- Re-elevation of coagulation parameters observed in limited patients; safety and effectiveness of repeat doses not established.
- Dose and Administration:
- Single dose of 5 gm (2 vials, each containing 2.5 gm).
- Administered IV as 2 consecutive infusions or by bolus injection of both vials via syringe.
- Supplied in packages of 2 single-use, 2.5 gm vials requiring refrigeration.
Criteria for 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Kcentra)
- Applies to: Apixaban, Rivaroxaban, Edoxaban, Dabigatran (used as nonspecific reversal agent when specific agents unavailable)
- Indication/Use: Use in DOAC associated life-threatening bleeding or need for emergent surgery/urgent procedures. (Off-label)
- Exclusion Criteria (ANY present -> NOT receive):
- Known anaphylactic or severe systemic reaction to 4F-PCC or any components (heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III, human albumin).
- Disseminated intravascular coagulation.
- History of heparin induced thrombocytopenia (4F-PCC contains heparin).
- Inclusion Criteria (ALL must be met):
- Patient has been taking a DOAC, and provider is reasonably certain that therapeutic anticoagulant levels are present (e.g., patient history and timing of last dose, laboratory testing if available).
- Specific reversal agent (idarucizumab for dabigatran) FDA approved for the patient’s condition is not readily available.
- Patient has life-threatening or critical site bleeding (e.g., ICH) OR is in need of a truly emergent procedure that cannot be delayed and where normal hemostasis is required.
- If reversal is desired in the setting of bleeding, standard measures for bleeding management (e.g., compression, surgical repair, volume replacement, hemodynamic support) are insufficient.
- Patient’s risk of thromboembolism is deemed less than the consequences of continued bleeding or delay of the procedure or surgery.
- Issues for Consideration:
- Off-label use: FDA approved for urgent reversal of vitamin K antagonists (VKA); used as nonspecific reversal agent for DOACs when specific agent unavailable. Evidence on use for DOAC reversal is low quality. Specific reversal agent preferred if available.
- Boxed Warning: Arterial and Venous Thromboembolic complications (fatal and nonfatal). Reversing anticoagulation exposes patients to thrombotic risk of underlying disease. Consider restarting anticoagulant therapy as soon as medically appropriate. More thromboembolic events occurred in trials vs plasma, especially in patients with history of thromboembolic event. Patients with recent thromboembolic event (past 3 months) excluded from trials; may not be suitable for such patients.
- Hypersensitivity reactions observed.
- Transmission risk: Blood-derived product manufactured using two virus reduction steps but still carries risk of transmitting infection.
- If 4F-PCC unavailable, activated PCC (aPCC, FEIBA) may be considered. Contains mainly nonactivated Factors II, IX, and X and mainly activated Factor VII. Generally less well studied than 4F-PCC for DOAC reversal. Single dose of 50 units per kg has been used.
- Dose and Administration:
- Doses vary: Single dose of 25 to 50 units per kg or fixed dose of 2,000 units IV.
- Dosing calculated based on quantity (international units) of factor IX in product (varies from vial to vial).
- Administered by IV infusion at rate of 0.12 ml/kg/min (~3 units/kg/min) up to maximum rate of 8.4 ml/min (~210 units/min).
- Supplied in single vials of 500 units and 1000 units requiring reconstitution; can be stored at 2-25°C.
General Principles for DOAC Reversal Agents
- Applies to: Apixaban, Rivaroxaban, Edoxaban, Dabigatran
- Use of reversal agents should be considered ONLY in severe, life-threatening bleeding and where potential risk of thromboembolism is deemed less than consequences of continued bleeding.
- DOACs have relatively short half-lives; bleeding often managed by temporarily discontinuing anticoagulant and providing supportive care (discontinuing anticoagulant, maintaining adequate diuresis, compression, surgical repair, fluid and/or blood replacement, hemodynamic support, and hemodialysis for dabigatran).
- Consider administration of activated charcoal for known recent DOAC ingestion within past 2-4 hours.
- Consider presence of other antithrombotic drugs (e.g., antiplatelet agents) and discontinue as appropriate.
- Use reserved for patients with known recent exposure to a DOAC.
- Consider restarting anticoagulant therapy as soon as medically appropriate due to elevated risk of thromboembolism.
- High quality data lacking; no randomized trial evidence demonstrating that administration of reversal agents improves clinical outcomes.
- No FDA approved products indicated for reversal of apixaban, rivaroxaban, or edoxaban (factor Xa inhibitors). Use of nonspecific agent such as 4F-PCC may be considered as part of treatment strategy (evidence limited). If 4F-PCC unavailable, aPCC (FEIBA) may be considered. Note: 4F-PCC and some aPCC contraindicated in patients with history of heparin induced thrombocytopenia (HIT).
- Facilities expected to have reversal agents readily and emergently available when clinically necessary; restrict to or oversee by locally designated specialty service(s) (e.g., Hematology, Critical care, Emergency Medicine, Neurology, Neurosurgery).